Chardan Capital Issues Optimistic Forecast for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Coya Therapeutics in a note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.03) per share for the year, up from their prior estimate of ($1.26). Chardan Capital has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Thursday.

Coya Therapeutics Price Performance

Shares of COYA traded down $0.01 on Thursday, reaching $6.56. The company's stock had a trading volume of 14,959 shares, compared to its average volume of 91,406. The stock has a market capitalization of $109.63 million, a P/E ratio of -10.08 and a beta of 0.31. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.24. The stock's 50 day simple moving average is $6.43 and its two-hundred day simple moving average is $6.52.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million.

Remove Ads

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently modified their holdings of the stock. DME Capital Management LP increased its holdings in Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after acquiring an additional 372,414 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics during the fourth quarter valued at about $74,000. Northern Trust Corp increased its holdings in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Coya Therapeutics during the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.